To study the clinical efficacy of Jianpi Shengxue Tablets in the treatment of patients with acute ischemic stroke and iron deficiency anemia.Methods:A total of of 192 patients with acute ischemic stroke and iron deficiency anemia admitted to Quanzhou First Hospital，Fujian between March 2017 and May 2018 were selected as the research objects and were randomly divided into an observation group and a control group，with 96 cases in each group.The observation group was given Jianpi Shengxue Tablets treatment，3 tablets/time，3 times/d，for 3 months; the control group was given Shengxuebao mixture treatment，15 mL/time，3 times/d，for 3 months.The related indexes of the 2 groups was compared.The rate of disability after 6 months of onset and the recurrence rate of ischemic stroke 1 year after onset and all-cause mortality were followed up.Results:At 3 months after treatment，the anemia of the observation group was significantly higher than that of the control group(P<0.05).The levels of serum IL-1β，TNF-α，CRP and hepcidin were significantly decreased in the observation group(P<0.05).The control group did not decrease significantly after treatment，and the inflammatory response transmitter level in observation group was significantly lower than the control group(P<0.05); the RET，RBC，and HGB levels in the observation group increased significantly(P<0.05)，and the control group did not significantly increase after treatment.The blood routine index of the observation group was significantly higher than that of the control group(P<0.05); the serum iron(SI)and transferrin saturation(TS)of the observation group were significantly increased and there was significant difference with the control group(P<0.05); the difference in adverse reactions between the 2 groups was not statistically significant(P>0.05); the disability rate of the observation group was significantly lower than that of the control group 6 months after the onset of follow-up(P<0.05); the observation group was significantly lower than the control group(P<0.05).The recurrence rate of ischemic stroke 1 year after the onset of follow-up was significantly lower in the observation group than in the control group(P<0.05).There was no significant difference in all-cause mortality between the 2 groups at 1 year after the follow-up(P>0.05).Conclusion:Jianpi Shengxue Tablets can effectively treat acute ischemic stroke with iron deficiency anemia and is safe and effective.It is worthy of clinical use in the treatment of ischemic stroke and anemia.